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Objective: The long-term outcomes of endovascular abdominal aortic aneurysm repair (EVAR) remain to be determined,
but patients with aneurysm shrinkage after EVAR appear to have a good prognosis. We previously observed that anti-
platelet therapy is a risk factor for lack of aneurysm shrinkage, a ﬁnding suggesting that coagulation and ﬁbrinolysis play
roles in shrinkage. We therefore studied the effect of antiﬁbrinolytic therapy with tranexamic acid (TXA) on aneurysm
shrinkage after EVAR.
Methods: From May 2007 to May 2012, EVAR was performed in 187 patients, 165 of whom had an enhanced computed
tomographic evaluation 6 months after their procedure. Six of the 165 patients were excluded from the study because
they had a type Ia endoleak or coil embolization to treat a type II endoleak#6 months after EVAR. Of the remaining 159
patients, 110 underwent EVAR before we started to use TXA in our centers. TXA therapy (1500 mg/d for 6 months)
began in January 2011, and 48 patients completed the treatment regimen. Patients not treated with TXA were compared
with those given TXA. Analyses to identify risk factors for lack of aneurysm shrinkage were performed.
Results: No patient had a thromboembolic event. There were no signiﬁcant differences between the no-TXA and TXA
groups in demographics, aneurysm characteristics, prosthesis implanted, type II endoleak occurrence during EVAR or 1
or 6 months afterward, or aneurysm shrinkage at 1 month. However, at 6 months after EVAR, the TXA group had
signiﬁcantly greater aneurysm shrinkage (P [ .035) and a signiﬁcantly higher percentage of patients with >4 mm in
shrinkage (P [ .010). Multiple regression analysis showed aneurysm diameter, type II endoleak 6 months after EVAR,
and TXA treatment were independently associated with aneurysm shrinkage or lack of shrinkage.
Conclusions: Antiﬁbrinolytic therapy with TXA was associated with aneurysm shrinkage after EVAR. Studies to identify
the dosage of TXA that is optimally safe and effective in this application, as well as investigations of the best timing and
route (parenteral vs oral) for TXA administration, are warranted. (J Vasc Surg 2014;59:1203-8.)Endovascular abdominal aortic aneurysm (AAA) repair
(EVAR) is widely and increasingly used because it has a
lower operative mortality rate than surgical AAA repair
and favorable short-term results. However, some random-
ized studies found that, over the long term (4 to 6 years),
patients who underwent EVAR had a survival rate similar
to or lower than that of patients given open repair as well
as signiﬁcantly higher rates of reinterventions and graft-
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rupture,3 and shrinkage of the sac is considered to indicate
successful exclusion of the AAA from the circulation and to
be a strong predictor of good long-term results.4,5
We previously found that multiagent antiplatelet ther-
apy was associated with a lack of aneurysm shrinkage after
EVAR.6 This ﬁnding suggests that a balance between coag-
ulation and ﬁbrinolysis plays a role in post-EVAR aneurysm
shrinkage and that administration of an antiﬁbrinolytic
agent might promote shrinkage.
Tranexamic acid (TXA) is a synthetic lysine analog that
binds reversibly to plasminogen, thereby blocking plasmin-
ogen activation and transformation to plasmin. Because
plasmin is responsible for the degradation of ﬁbrin, a pro-
tein that forms the framework of blood clots, TXA exerts
its antiﬁbrinolytic effect by inhibiting ﬁbrin degradation.
We therefore conducted a study to determine whether
administration of TXA affected aneurysm shrinkage in pa-
tients who had undergone EVAR.
METHODS
This study was a retrospective review of the medical
records of patients who underwent EVAR from May
2007 to May 2012 at ﬁve institutions. The study protocol,
including the administration of TXA, was approved by the1203
Table I. Baseline and operative characteristics of patients
who were and were not treated with tranexamic acid
(TXA) after endovascular abdominal aortic aneurysm
repair (EVAR)
Variablea
No TXA
(n ¼ 110)
TXA
(n ¼ 48) P
Patient characteristics
Age, years 76.3 6 8.2 76.2 6 7.2 .933
Female gender 19 (17) 7 (15) .675
Hypertension 80 (73) 39 (81) .253
Hyperlipidemia 39 (35) 23 (48) .140
Diabetes mellitus,
type 1 or 2
19 (17) 7 (15) .675
Current smoker 75 (68) 34 (71) .740
Chronic obstructive
pulmonary disease
18 (16) 11 (23) .328
Antiplatelet therapyb 53 (48) 30 (63) .097
Multiagent antiplatelet
therapy
33 (30) 18 (38) .354
Anticoagulation
therapy, warfarin
8 (7) 7 (15) .149
Aneurysm characteristics
Proximal neck length,
mm
27 6 9 27 6 10 .765
Suprarenal angle, 21 6 21 28 6 24 .079
Proximal neck angle, 42 6 26 43 6 29 .900
Maximum diameter,
mm
51.4 6 8.2 53.4 6 10.5 .200
Type of prosthesisc .184
Zenith 50 (45) 20 (41)
Excluder 44 (40) 18 (38)
Powerlink 16 (15) 8 (17)
Endurant 0 2 (4)
Operating time, min 129 6 48 134 6 39 .550
aContinuous data are presented as the mean 6 standard deviation and
categoric data as number (%).
bIncluding aspirin alone.
cThe manufacturers are Zenith: Cook, Bloomington, Ind; Excluder: W. L.
Gore and Associates, Flagstaff, Ariz; Powerlink: Endologix, Irvine, Calif;
and Endurant: Medtronic, Minneapolis, Minn.
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informed consent to their participation. Of the 187
patients identiﬁed as having undergone EVAR during the
study period, the study initially enrolled only the 165
who had an enhanced computerized tomographic evalua-
tion 6 months after the procedure. The study subsequently
excluded four patients who had a type Ia endoleak and two
who underwent transarterial coil embolization for a type II
endoleak #6 months of EVAR. Of the remaining patients,
110 had undergone EVAR before we began to administer
TXA after the procedure (ie, before the end of 2011).
Beginning in January 2011, patients who underwent
EVAR at our institutions received TXA (1500 mg/d orally)
from the morning after EVAR until 6 months afterward.
All patients returned for an outpatient visit at our hospitals
every 4 to 8 weeks during those 6 months, and their
compliance with TXA therapy was assessed at each visit.
Forty-eight patients completed the entire TXA treatment
regimen. TXA therapy was discontinued in another patient
because of development of deep vein thrombosis 3 months
after EVAR, even though it could not be determined
whether TXA had caused the problem. This patient was
excluded from further analysis.
Patient demographics, concomitant diseases, aneurysm
characteristics, endovascular device implanted, operating
time, and postoperative antiplatelet and anticoagulation
therapy in patients in the TXA and no-TXA groups were
compared by using the nonpaired t-test and c2 test. Multi-
agent antiplatelet therapy was deﬁned as treatment with
aspirin and clopidogrel bisulfate, ticlopidine hydrochloride,
or cilostazol. In our institutions, antiplatelet therapy or
anticoagulation therapy using warfarin is not stopped
before EVAR.
Data from the 158 patients in the study were entered
into a univariant analysis of factors possibly associated
with aneurysm shrinkage at 1 and 6 months after EVAR.
The univariant analysis used the nonpaired t-test, c2 test,
and regression analysis. Variables found by this analysis to
be associated with aneurysm shrinkage with a P value
of <.10 were evaluated for a possible relationship with
shrinkage in a multivariant assessment using multiple
regression analysis. The effect of TXA therapy on aneurysm
shrinkage in patients without and with a type II endoleak
6 months after EVAR and in patients not receiving and
receiving multiagent antiplatelet therapy was evaluated by
using c2 testing. A P value of<.05 was considered to repre-
sent a signiﬁcant correlation. All statistical analyses were
done with StatView 4 software (SAS Institute, Cary, NC).
RESULTS
At baseline (before or during EVAR), patients who
received TXA were similar to those not given TXA with
respect to all assessed characteristics (Table I), except that
they were somewhat more likely to have received antiplate-
let therapy (P ¼ .097) and their suprarenal angle tended to
be larger (P ¼ .079). Preoperatively, patients in the no-
TXA group had a maximum aneurysm diameter of 39 to
80 mm, whereas the maximum diameter in the TXA groupwas 40 to 85 mm. The percentage of patients in each group
with a large maximum aneurysm diameter was similar: 16%
in the no-TXA group and 23% in the TXA group for aneu-
rysms >59 mm (P ¼ .259); 9% and 15%, respectively, for
aneurysms >64 mm (P ¼ .306); and 5% and 10%, respec-
tively, for aneurysms >69 mm (P ¼ .163). Deep vein
thrombosis developed in one patient, although whether
this was related to TXA therapy could not be determined.
No other patient in either group had a thromboembolic
event (eg, acute coronary syndrome or cerebral infarction)
during the study period.
At 1 month after EVAR, the TXA and no-TXA groups
had a similar amount of aneurysm shrinkage. At 6 months,
however, patients given TXA had signiﬁcantly greater
shrinkage (6.0 6 4.8 mm vs 4.3 6 4.8 mm; P ¼ .035).
Moreover, a signiﬁcantly higher percentage of TXA-
treated patients than untreated patients had shrinkage
of >4 mm (58% [n ¼ 28] vs 36% [n ¼ 40]; P ¼ .010).
No patient in either group had an aneurysm enlargement
of >4 mm.
Table II. Results of univariant analysis of factors possibly
associated with aneurysm shrinkage after endovascular
abdominal aortic aneurysm repair (EVAR) in 158 patients
Variable No. Resultsa P
Patient characteristics
Age y ¼ 8.2  0.05xb .361
Gender .918
Female 26 4.9 6 4.7
Male 132 4.8 6 4.9
Hypertension .371
Absent 39 4.2 6 4.9
Present 119 4.9 6 4.9
Hyperlipidemia .187
Absent 96 5.2 6 5.1
Present 62 4.2 6 4.4
Diabetes mellitus
(type 1 or 2)
.808
Absent 132 4.9 6 4.7
Present 26 5.0 6 5.6
Smoking status .257
Nonsmoker 49 4.1 6 4.3
Current smoker 109 5.1 6 5.1
Chronic obstructive
pulmonary disease
.529
Absent 129 4.7 6 4.8
Present 29 5.3 6 5.3
Antiplatelet therapy
including aspirin alone
.082
Not receiving 75 5.5 6 5.0
Receiving 83 4.2 6 4.7
Aspirin-alone antiplatelet
therapy
.877
Not receiving 126 4.8 6 4.9
Receiving 32 4.7 6 4.8
Multiagent antiplatelet
therapy
.085
Not receiving 107 5.3 6 4.9
Receiving 51 6.7 6 5.8
Aneurysm characteristics
Proximal neck length y ¼ 7.5  0.10x .023
Suprarenal angle y ¼ 4.2 þ 0.02x .180
Proximal neck angle y ¼ 3.6 þ 0.03x .111
Maximum diameter y ¼ 5.1 þ 0.19x <.001
Type II endoleak
On EVAR completion
angiogram
.284
No 113 5.1 6 5.1
Yes 45 4.1 6 4.3
1 month after EVAR on
enhanced CT
<.001
No 110 5.8 6 5.0
Yes 48 2.6 6 3.6
6 months after EVAR on
enhanced CT
<.001
No 110 6.1 6 5.0
Yes 48 1.9 6 3.1
TXA therapy .035
No 110 4.3 6 4.8
Yes 48 6.0 6 4.8
CT, Computed tomography; TXA, tranexamic acid.
aThe plus-minus values aremean6 standard deviationmillimeters of shrinkage.
by represents aneurysm shrinkage (mm); x represents each factor.
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observed in 27% of patients in the no-TXA group (n ¼
30) and in 38% in the TXA group (n ¼ 18); the difference
was not signiﬁcant (P ¼ .259). There was also no signiﬁ-
cant difference in type II endoleak occurrence between
patients receiving (31.3% [15 of 48]) and not receiving
(32.7% [36 of 110]) multiagent antiplatelet therapy (P >
.999) or between patients receiving (33.3% [5 of 15])
and not receiving (30.1% [43 of 143]) anticoagulant ther-
apy (P ¼ .774).
The univariant analysis showed that the TXA therapy,
the presence of a type II endoleak at 1 month or 6 months
after EVAR, proximal neck length, and preoperative
maximum aneurysm diameter were each signiﬁcantly associ-
ated with aneurysm shrinkage (Table II). Moreover, anti-
platelet therapy and multiagent antiplatelet therapy were
each somewhat associated with aneurysm shrinkage
6months after EVAR. Themultivariant analysis of these fac-
tors found that a type II endoleak 6months after EVAR, pre-
operative maximum aneurysm diameter, and TXA therapy
were each signiﬁcantly associated with aneurysm shrinkage
or lack of shrinkage at 6 months after EVAR (Table III).
The assessment of the effect of TXA therapy on aneu-
rysm shrinkage in patients without and with a type II endo-
leak 6 months after EVAR (Fig 1) found that among those
without an endoleak, aneurysm shrinkage occurred in 80%
(24 of 30) of patients given TXA and in 45% (36 of 80) not
given TXA, with the difference being signiﬁcant (P ¼
.0015). Among patients with a type II endoleak, the per-
centage of those with aneurysm shrinkage was low in the
no-TXA (13% [4 of 30]) and the TXA group (22% [4 of
18]), with no signiﬁcant difference between groups.
The analysis of the effect of TXA on aneurysm
shrinkage in patients not receiving and receiving multi-
agent antiplatelet therapy (Fig 2) showed that among those
not given TXA, a signiﬁcantly lower percentage of patients
who were receiving (15% [5 of 38]) this antiplatelet
regimen had aneurysm shrinkage compared with those
not receiving (46% [35 of 87]) antiplatelet therapy (P ¼
.0025). Among patients given TXA, multiagent antiplatelet
therapy had no signiﬁcant effect on aneurysm shrinkage,
which occurred in 61% (11 of 29) of patients receiving an-
tiplatelet agents and in 57% (17 of 47) not given those
agents (P > .999).
DISCUSSION
The goal of EVAR is to prevent aneurysm rupture by
completely excluding the aneurysm from the circulation.
Aneurysm shrinkage has been reported to be a favorable
long-term outcome of EVAR.4,5 The presence of a high-
pressure endoleak (type I or type III) is an important risk
factor for a lack of aneurysm shrinkage and aneurysm
rupture,7-9 but whether a type II endoleak has similar
effects remains unknown. We previously observed that
patients with a type II endoleak alone (no type I or III)
had an increased risk of a lack of aneurysm shrinkage after
EVAR, although shrinkage did occur in some patients,
perhaps because they had a different endoleak subtype.6We also found that multiagent antiplatelet therapy was
independently associated with a lack of aneurysm
shrinkage.
PP
Fig 1. Percentage of patients with aneurysm shrinkage of >4 mm,
according to whether they were treated with tranexamic acid
(TXA) and had a type II endoleak 6 months after endovascular
abdominal aortic aneurysm repair (EVAR).
Table III. Results of multiple regression analysis of
factors possibly associated with aneurysm shrinkage at
6 months after endovascular abdominal aortic aneurysm
repair (EVAR) in 158 patients
Variable r Error t P
Antiplatelet therapy
including aspirin
0.065 0.904 0.695 .488
Multiagent antiplatelet
therapy
0.090 0.857 0.972 .332
Aneurysm proximal
neck length
0.086 0.039 1.188 .237
Maximum aneurysm
diameter
0.231 0.040 3.155 .002
Type II endoleak
1 month after EVAR 0.075 0.947 0.835 .405
6 months after
EVAR
0.330 0.953 3.654 <.001
TXA therapy 0.199 0.737 2.846 .005
TXA, Tranexamic acid.
P = .0025
P > .9999
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Fig 2. Percentage of patients with aneurysm shrinkage of >4 mm,
according to whether they were treated with tranexamic acid
(TXA) and with multiagent antiplatelet (AP) therapy after endo-
vascular abdominal aortic aneurysm repair (EVAR).
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cludes the feeding artery is required to stop blood pressure
transmission in an aneurysm.10 After EVAR, clotting of the
blood trapped between the stent graft and the aneurysm
wall should occur. Engellau et al11 used magnetic reso-
nance imaging to assess the clot in the aneurysm sac after
EVAR in 15 patients and detected an organized clot in
two at 1 month after the procedure, in three of 12 patients
at 6 months, and in four of 10 patients at 12 months;
therefore, it appears that an organized clot does not
develop in all patients who undergo EVAR. If the clot
does not become organized, blood pressure associated
with a type II endoleak or small artery not detectable by
enhanced computed tomography would be transmitted
to the aneurysm sac and the aneurysm would not shrink.In light of our previous ﬁndings, we hypothesized
that multiagent antiplatelet therapy might be a risk factor
for a lack of aneurysm shrinkage because it inhibits clot orga-
nization. In patients with aneurysm shrinkage despite the
presence of a type II endoleak, blood pressure from the endo-
leak may not be transmitted to the aneurysm wall because
of the presence of an organized clot in the aneurysm sac.
Whether a clot becomes organized depends on a bal-
ance between coagulation and ﬁbrinolysis. The presence
of an AAA, usually with mural thrombus, constitutes a pro-
thrombotic diathesis.12 In a study of changes in coagula-
tion and ﬁbrinolysis immediately after EVAR, Englberger
et al13 found that coagulation activity, with hyperﬁbrinoly-
sis, increased on the ﬁrst day after the procedure and sub-
sided#5 days. Monaco et al14 reported that platelet counts
and levels of coagulation factors were decreased on the
ﬁrst, ﬁfth, and 10th days after EVAR, whereas levels of
D-dimer and ﬁbrin degradation products were increased.
Thus, consumption of coagulation factors as a result of
clot formation in the aneurysm sac and hyperﬁbrinolysis
appeared to occur acutely after EVAR and, according to
Monaco et al,14 lasted for w1 month. However, Aho
et al15 reported that levels of D-dimer, thrombin-
antithrombin III complex, and prothrombin fragment
1 þ 2 were high for 3 months after EVAR, and Bailey
et al16 found that they were high for 5 months. In a study
of ﬁbrinolytic activity for 12 months after EVAR, Abdelha-
mid et al17 observed that ﬁbrinolysis was increased for the
ﬁrst 6 months, as were levels of serum P-selectin, a marker
of platelet activity. The ﬁndings of these studies indicate
that prothrombotic diathesis, with hyperﬁbrinolysis, con-
tinues for several months after EVAR.
JOURNAL OF VASCULAR SURGERY
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terations in coagulation and ﬁbrinolysis after EVAR was
investigated by Serino et al,18 who compared D-dimer
levels in patients in whom the aneurysm had decreased in
size (>6 months after EVAR) with levels in patients with
an enlarged or unchanged aneurysm. They found that pa-
tients in the latter group had signiﬁcantly higher levels. In a
study by Conelissen et al19 in 14 patients with an aneurysm
that had not decreased by a mean of 2 years after EVAR,
magnetic resonance imaging showed that the clot in the
sac was not organized in half those patients.
On the basis of these ﬁndings, we speculated that
AAAs might shrink after EVAR if clot organization in the
aneurysm sac were promoted by activation of coagulation
or inhibition of ﬁbrinolysis. Activation of coagulation
would not be practical, however, because it already occurs
after EVAR. Furthermore, replenishment of platelets or
coagulation factors by transfusing platelet-rich or fresh-
frozen plasma might pose a risk of infection transmission.
In contrast, suppression of ﬁbrinolysis might be a feasible
approach.
Several antiﬁbrinolytic drugs have been evaluated over
the years.20,21 Aprotinin, a broad-spectrum serine protease
inhibitor given intravenously, was withdrawn from the
market in 2008 because of an increase in mortality among
high-risk patients undergoing cardiac surgery.20 Adminis-
tration of ε-aminocaproic acid, a synthetic lysine analog,
has been associated with onset of hypotension, cardiac ar-
rhythmias, myopathy, and rhabdomyolysis.20 TXA, another
synthetic lysine analog, prevents the degeneration of
ﬁbrin21 and has been used safely for several decades, pri-
marily to mitigate the risk of bleeding after surgery.20
In Japan, TXA is approved for treatment only not of
systemic bleeding disorders but also disorders in which
local hyperﬁbrinolysis may be involved. TXA can be given
intramuscularly, intravenously, or orally. Adverse events
reported to be associated with TXA treatment include
anorexia, drowsiness, itching, rash, and a transient defect
in color vision; such effects occur in <1% of patients.22
In randomized studies, no marked increase in thrombosis
after administration of TXA was observed, even in cases
in which a thrombotic complication was anticipated and
even when the agent was given during an operation.23,24
The plasma TXA concentration found to be effective in
obtaining antiﬁbrinolysis has been reported to range from 5
to 15 mg/L, and when 1300 mg TXA was given orally for
5 days, the peak plasma concentration was 16.4 mg/L.24
In Japan, TXA is available in 250-mg capsules, and patients
in the TXA group in our study took six of these daily.
Overall, these patients had signiﬁcantly greater aneurysm
shrinkage than those not given TXA. Moreover, multivar-
iant analysis found that TXA treatment was signiﬁcantly
associated with aneurysm shrinkage at 6 months after
EVAR, and shrinkage of >4 mm was observed in 80% of
patients without a type II endoleak. In the European Col-
laborators on Stent-Graft Techniques for Abdominal
Aortic Aneurysm Repair (EUROSTAR) study of EVAR
outcomes, the maximum change in aneurysm diameterwas <8 mm in 84% of 6337 patients without any detect-
able endoleaks.25 Our ﬁndings suggest that antiﬁbrinolytic
therapy with TXA may be effective in achieving aneurysm
shrinkage in such patients. Many patients with AAAs are
receiving antiplatelet therapy for coexistent coronary artery
or cerebral vascular disease. TXA may be especially useful in
these patients by modifying the adverse effect of antiplate-
let therapy on aneurysm shrinkage after EVAR without
increasing the risk of thromboembolic complications.
Agents other than TXA that have been found to increase
aneurysm shrinkage after EVAR include doxycycline,26 a
matrix metalloprotease inhibitor, statins,27 and calcium
channel blockers.28 Perhaps a post-EVAR regimen com-
bining antiﬁbrinolytic therapy with one or more of these
medications might be more effective in promoting AAA
shrinkage. We found that administration of TXA alone was
associated with aneurysm shrinkage only in patients who
did not have a type II endoleak 6 months after EVAR.
Our study had the usual limitations of a nonrandom-
ized investigation that included historical controls. We
also did not evaluate the effect of TXA therapy on the
coagulation and ﬁbrinolysis systems by measuring levels
of D-dimer, ﬁbrin degradation products, and thrombin-
antithrombin III complex. In addition, oral TXA therapy
was started the morning after the EVAR procedure, but
any blood trapped in the aneurysm sac would begin to
clot just after stent graft deployment. Therefore, parenteral
administration of TXA during EVAR, followed by oral
administration afterward, might have been more effective.
CONCLUSIONS
Despite the limitations, we consider our results with
TXA to be promising and suggest that studies to identify
the dosage of the agent that is optimally safe and effective
in obtaining aneurysm shrinkage after EVAR, as well as in-
vestigations of the most favorable timing and route (paren-
teral, oral, or a combination of the two) of TXA
administration, are warranted.
We thank Renée J. Robillard, MA, ELS, for editorial
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